Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Left Right & Center is for listeners who feel like people on the other side of the political divide are on Mars. David Greene pieces together the big picture by inviting people from the left and the ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

The city’s towering challenges include an abandoned skyscraper covered in graffiti. At David Kordansky Gallery, it inspires a tower of its own. By Jonathan Griffin and Carlos Jaramillo The institution ...

Protein design (or protein engineering) is a technique by which proteins with enhanced or novel functional properties are created. Proteins can be engineered by rational design, which typically uses ...